EverBlu Capital’s Adam Blumenthal will step down as chairman of Creso Pharma after the corporate regulator asked the company to produce documents linked to an investigation into suspected share trading contraventions.
“Creso Pharma appears to have become involved in the ASIC investigation because of common directorships between it and its corporate adviser, EverBlu Capital,” Creso said in a statement to the ASX, after halting its shares for two days.
Loading...
Jemima Whyte writes on business, specialising in companies, capital markets and innovation. Jemima has reported on business for The Australian Financial Review for more than 13 years. Email Jemima at jemima.whyte@afr.com
Liam Walsh writes on investigations and companies with The Australian Financial Review. He has won multiple media awards, worked in Japan and is now based in Brisbane. Email Liam at liam.walsh@afr.com.au
